<DOC>
	<DOC>NCT01741142</DOC>
	<brief_summary>The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.</brief_summary>
	<brief_title>Efficacy and Safety Study of ABT-436 in Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Has a primary Diagnostic and Statistical Manual of Mental DisordersFourth EditionText Revision diagnosis of major depressive disorder without psychotic features No current antidepressant treatment within 7 halflives or 2 weeks, whichever is longer, prior to Day minus 1. Can safely be treated on an outpatient basis. A condition of general good physical health. Surgically sterile, using a highly effective method of birth control or (if female) at least 1 year post menopausal. History of hypersensitivity, intolerance or adverse reaction to escitalopram that led to discontinuation, or hypersensitivity to citalopram. History of serotonin syndrome. Inadequate response to more than two different antidepressant medications during the current major depressive episode. History of electroconvulsive therapy, vagal nerve stimulation or deep brain stimulation. History of transcranial magnetic stimulation during the current major depressive episode. Psychotherapy that has not been ongoing for at least 3 months prior to Day minus 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
</DOC>